Navigation Links
Arizona Heart Innovative Technologies Licenses New Endovascular Device
Date:11/12/2008

PHOENIX, Nov. 12 /PRNewswire/ -- Arizona Heart Innovative Technologies, LLC (AHIT) announced the license of a new medical device for endovascular use to a publicly traded medical device company. "This is the second AHIT-developed product that we have licensed in the past ten months. We continue to demonstrate our ability to bridge the gap between good ideas from the medical community to commercially viable products for medical device companies. This confirms the viability of our business model to serve as a cost-effective supplementary research and development resource for companies," says AHIT President and CEO, Bill Colone. "We have additional products that have completed the development process and we are continuing to discuss options with many device companies."

AHIT licensed the endovascular product in July of 2007 from Hani Shennib, MD, a cardiovascular surgeon formerly at the Arizona Heart Hospital. The product was prototyped, tested and marketed to multiple medical companies immediately following positive clinical test results. The product should reach both the U.S. and international markets by the first quarter of 2009.

About Arizona Heart Innovative Technologies, LLC

Bill Colone, who co-founded AHIT in August 2006, has over 26 years of experience in developing and marketing medical devices. He served as President of Endomed, Inc. for over ten years, until its sale to LeMaitre Vascular (LMAT) in February 2005. Bill holds eleven US patents for medical devices with other applications pending.

AHIT provides a vehicle for evaluating and commercializing ideas from the medical community. This process includes product due diligence, market research, securing intellectual property rights, prototyping, and matching the product to the best medical device company through a sales process. The company's Scientific Advisory Board (SAB) consists of cardiovascular surgeons and endovascular specialists with over 80 years of experience trea
'/>"/>

SOURCE Arizona Heart Innovative Technologies, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
3. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
4. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
5. ThirdBiotech Launches Research Institute to Promote Formation and Growth of Arizona-Based Biotech Companies
6. First Annual Arizona Biotech Day Announced for October 23rd 2008
7. Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval
8. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
9. ATS Medical Expands Open Pivot Heart Valve Offerings
10. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
11. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015  Kerastem Technologies announce that the Company ... FDA Center For Biologics Evaluation and Research (CBER) Office ... clinical trial investigating the safety and feasibility of the ... male pattern baldness (androgenic alopecia). The phase ... clinical work in Europe and ...
(Date:7/28/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results for ... "Orenitram ®  sales grew nearly 300% as compared ... product was first launched," said Roger Jeffs, Ph.D., ... growth in Orenitram sales was due to an ...
(Date:7/27/2015)... Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), ... treatment of cancer, today provides the following financial update. ... $1,000,000 unit offering private placement.  This financing is a ... at a price of $0.06 per unit.  Each unit ... share purchase warrant.  Each whole warrant is exercisable into ...
(Date:7/27/2015)... July 27, 2015 Research presented at the ... expand on the studies that led to a fingerprick ... for this disease to receive approval from the World ... breaking Ebola,s grip on West Africa ... enabling healthcare workers to isolate and treat these patients ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Quest PharmaTech Closes $1,000,000 Private Placement 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged ... of human viral and other infectious diseases, today reported unaudited ... 31, 2008. At December 31, 2008, Idenix,s cash, cash equivalents ... , ...
... Audit Confirms Responsible Use. , ... Wilmington, DE (Vocus) ... have verified its plant biotechnology research and development processes are in ... its North American operations. The ETS third-party audit confirms that ...
... ON LICENSING, FUNDING, ACQUISITION AND INFORMATION MANAGEMENT INITIATIVES TO ACCELERATE ... Sinobiomed Inc. ("Sinobiomed," or "the Company") (OTC Bulletin Board: SOBM) ... management team to accelerate the Company,s growth. The new management ... , Dr. Anchie ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7DuPont Biotech Stewardship Program Gains External Certification 2DuPont Biotech Stewardship Program Gains External Certification 3Sinobiomed Announces New Executive Team 2Sinobiomed Announces New Executive Team 3
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... first time, researchers have discovered a disease mechanism that links ... of ALS -- and points to a possible therapeutic target. ... in the journal Nature Neuroscience . ALS is ... and death within three to five years of diagnosis. ...
... ongoing concern about plastic waste accumulating in municipal landfills, ... are reporting development of a new ultra-light biodegradable foam ... in milk and ordinary clay. The new substance could ... products, they report in the ACS, Biomacromolecules , ...
... ever on the verge of suicide, requiring the close ... cells from pulling the trigger. This self-destructive tendency can ... cells are permitted to kill themselves, but it can ... memories, for instance. Rockefeller University scientists are parsing this ...
Cached Biology News:Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3'Reaper' protein strikes at mitochondria to kill cells 2
SRY (sex determining region Y)-box 10...
Complement C1r [Human]...
biotin-4-fluorescein...
... LVF-CUV-ADP, FHS-LVF and CVD-Diffuse We've combined ... Filters to create the world's first notch ... adjustable bandpass. Each filter features an excellent ... These filters -- with interference coatings ...
Biology Products: